Cara Therapeutics (CARA) Misses Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Cara Therapeutics (CARA) Misses Q2 EPS by 1c

Cara Therapeutics Reports Second Quarter 2015 Financial Results

August 10, 2015 4:01 PM EDT

Reported statistically-significant positive top-line results from Phase 2 trial for I.V. CR845 in uremic pruritus

Completed successful public offering of common stock, raising net proceeds of $75.1 million

First Pivotal trial for I.V. CR845 in acute pain on track to begin in 3Q'15

Conference call today at 4:30 p.m. ET

SHELTON, Conn., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ: CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by... More